Browse IKBKE

Summary
SymbolIKBKE
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
Aliases IKKE; IKK-i; KIAA0151; IKK-E; IKKI; I-kappa-B kinase epsilon; IKK-epsilon; IKK-related kinase epsilon; induc ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus. Nucleus, PML body Note=Targeting to PML nuclear bodies upon DNA damage is TOPORS-dependent (PubMed:20188669). Located diffusely throughout the cytoplasm but locates to punctate cytoplasmic bodies when coexpressed with TRIM6 (PubMed:24882218).
Domain PF00069 Protein kinase domain
Function

Serine/threonine kinase that plays an essential role in regulating inflammatory responses to viral infection, through the activation of the type I IFN, NF-kappa-B and STAT signaling. Also involved in TNFA and inflammatory cytokines, like Interleukin-1, signaling. Following activation of viral RNA sensors, such as RIG-I-like receptors, associates with DDX3X and phosphorylates interferon regulatory factors (IRFs), IRF3 and IRF7, as well as DDX3X. This activity allows subsequent homodimerization and nuclear translocation of the IRF3 leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNB. In order to establish such an antiviral state, IKBKE forms several different complexes whose composition depends on the type of cell and cellular stimuli. Thus, several scaffolding molecules including IPS1/MAVS, TANK, AZI2/NAP1 or TBKBP1/SINTBAD can be recruited to the IKBKE-containing-complexes. Activated by polyubiquitination in response to TNFA and interleukin-1, regulates the NF-kappa-B signaling pathway through, at least, the phosphorylation of CYLD. Phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. In addition, is also required for the induction of a subset of ISGs which displays antiviral activity, may be through the phosphorylation of STAT1 at 'Ser-708'. Phosphorylation of STAT1 at 'Ser-708' seems also to promote the assembly and DNA binding of ISGF3 (STAT1:STAT2:IRF9) complexes compared to GAF (STAT1:STAT1) complexes, in this way regulating the balance between type I and type II IFN responses. Protects cells against DNA damage-induced cell death. Also plays an important role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, wich leads to a negative impact on insulin sensitivity. Phosphorylates AKT1.

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002756 MyD88-independent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007252 I-kappaB phosphorylation
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0009615 response to virus
GO:0010876 lipid localization
GO:0010883 regulation of lipid storage
GO:0010884 positive regulation of lipid storage
GO:0019915 lipid storage
GO:0031349 positive regulation of defense response
GO:0032479 regulation of type I interferon production
GO:0032480 negative regulation of type I interferon production
GO:0032606 type I interferon production
GO:0034340 response to type I interferon
GO:0035456 response to interferon-beta
GO:0035666 TRIF-dependent toll-like receptor signaling pathway
GO:0038061 NIK/NF-kappaB signaling
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0051235 maintenance of location
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0097193 intrinsic apoptotic signaling pathway
GO:0098586 cellular response to virus
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0004704 NF-kappaB-inducing kinase activity
GO:0005057 receptor signaling protein activity
GO:0008384 IkappaB kinase activity
GO:0031593 polyubiquitin binding
GO:0031625 ubiquitin protein ligase binding
GO:0032182 ubiquitin-like protein binding
GO:0036435 K48-linked polyubiquitin binding
GO:0043130 ubiquitin binding
GO:0044389 ubiquitin-like protein ligase binding
Cellular Component GO:0010008 endosome membrane
GO:0016604 nuclear body
GO:0016605 PML body
GO:0044440 endosomal part
> KEGG and Reactome Pathway
 
KEGG hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
hsa04623 Cytosolic DNA-sensing pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-936964: Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-918233: TRAF3-dependent IRF activation pathway
R-HSA-933541: TRAF6 mediated IRF7 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolIKBKE
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
Aliases IKKE; IKK-i; KIAA0151; IKK-E; IKKI; I-kappa-B kinase epsilon; IKK-epsilon; IKK-related kinase epsilon; induc ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IKBKE and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolIKBKE
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
Aliases IKKE; IKK-i; KIAA0151; IKK-E; IKKI; I-kappa-B kinase epsilon; IKK-epsilon; IKK-related kinase epsilon; induc ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IKBKE in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolIKBKE
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
Aliases IKKE; IKK-i; KIAA0151; IKK-E; IKKI; I-kappa-B kinase epsilon; IKK-epsilon; IKK-related kinase epsilon; induc ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IKBKE in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0480.867
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1150.922
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1620.841
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1860.604
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3750.814
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.050.979
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1880.528
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0830.94
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2970.812
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1140.263
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IKBKE in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.611.1-8.50.299
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 2213023.1-23.10.0437
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIKBKE
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
Aliases IKKE; IKK-i; KIAA0151; IKK-E; IKKI; I-kappa-B kinase epsilon; IKK-epsilon; IKK-related kinase epsilon; induc ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IKBKE. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIKBKE
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
Aliases IKKE; IKK-i; KIAA0151; IKK-E; IKKI; I-kappa-B kinase epsilon; IKK-epsilon; IKK-related kinase epsilon; induc ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IKBKE. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IKBKE.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIKBKE
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
Aliases IKKE; IKK-i; KIAA0151; IKK-E; IKKI; I-kappa-B kinase epsilon; IKK-epsilon; IKK-related kinase epsilon; induc ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IKBKE. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIKBKE
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
Aliases IKKE; IKK-i; KIAA0151; IKK-E; IKKI; I-kappa-B kinase epsilon; IKK-epsilon; IKK-related kinase epsilon; induc ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IKBKE expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIKBKE
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
Aliases IKKE; IKK-i; KIAA0151; IKK-E; IKKI; I-kappa-B kinase epsilon; IKK-epsilon; IKK-related kinase epsilon; induc ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IKBKE and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIKBKE
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
Aliases IKKE; IKK-i; KIAA0151; IKK-E; IKKI; I-kappa-B kinase epsilon; IKK-epsilon; IKK-related kinase epsilon; induc ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IKBKE collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.